{"id":3391,"date":"2025-08-28T22:54:56","date_gmt":"2025-08-29T02:54:56","guid":{"rendered":"http:\/\/www.arraysbank.com\/blog\/?p=3391"},"modified":"2025-08-28T23:01:44","modified_gmt":"2025-08-29T03:01:44","slug":"high-quality-ffpe-tissue-samples-for-egfr-research-in-non-small-cell-lung-cancer","status":"publish","type":"post","link":"https:\/\/www.arraysbank.com\/blog\/high-quality-ffpe-tissue-samples-for-egfr-research-in-non-small-cell-lung-cancer\/","title":{"rendered":"High-Quality FFPE Tissue Samples for EGFR Research in Non-Small Cell Lung Cancer"},"content":{"rendered":"

NSCLC FFPE Tissue Blocks with EGFR Mutation: Advancing Precision Oncology<\/h1>\n

Introduction to NSCLC and EGFR<\/a><\/h2>\n

Non-small cell lung cancer (NSCLC)<\/strong> <\/a>is the most common form of lung cancer, representing about 85% of cases globally. Research has shown that genetic alterations are critical in understanding tumor behavior, with EGFR (epidermal growth factor receptor) mutations<\/strong> among the most important biomarkers. These mutations play a key role in tumor growth, therapy selection, and prognosis. For researchers aiming to accelerate biomarker discovery, the nsclc ffpe tissue block<\/strong> provides a reliable and reproducible format for studying EGFR-driven lung cancer.<\/p>\n

What Are FFPE Tissue Samples?<\/h2>\n

FFPE (formalin-fixed paraffin-embedded) tissue samples<\/strong> are widely used in both research and clinical pathology. In this process, tumor tissue is fixed in formalin to preserve cellular structures and embedded in paraffin blocks for long-term storage. This method allows samples to remain stable for years while retaining sufficient antigenicity for immunohistochemistry (IHC), polymerase chain reaction (PCR), and next-generation sequencing (NGS).<\/p>\n

Using an ffpe tissue sample<\/strong> ensures researchers can access annotated material that is consistent and cost-effective. For NSCLC studies, this format provides large-scale availability of tumor blocks that can be sectioned repeatedly for biomarker validation.<\/p>\n

Role of EGFR in NSCLC<\/a> Research<\/h2>\n

Mutations in EGFR<\/strong> occur in approximately 10\u201315% of NSCLC patients in Western populations and up to 40% in Asian populations. These alterations are predictive markers for response to tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and osimertinib. Access to nsclc ffpe tissue blocks with EGFR mutation<\/strong> allows researchers to evaluate treatment response, resistance mechanisms, and novel therapeutic strategies.<\/p>\n

By studying egfr-positive ffpe tissue samples for lung cancer research<\/strong>, investigators can identify genetic signatures that improve patient selection for targeted therapies and explore how resistance evolves over time.<\/p>\n

Applications of NSCLC FFPE Tissue Blocks<\/h2>\n

The availability of non-small cell lung cancer<\/a> ffpe blocks<\/strong> annotated with EGFR status opens multiple avenues of research:<\/p>\n